08/27/2025 09:05
New NETSCOUT Research Confirms DDoS Continues to Dominate the Digital Battlefield, Destabilizing Critical Infrastructure

NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT), today released its latest research detailing the evolving Distributed Denial-of-Service (DDoS) attack landscape. NETSCOUT monitored more than 8 million DDoS attacks globally in the first half of 2025, including more than 3.2 million in EMEA. DDoS attacks have evolved into precision-guided weapons of geopolitical influence capable of destabilizing critical infrastructure. Hacktivist groups like NoName057(16) orchestrated hundreds of coordinated strikes e...

09/17/2025 16:09
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder

Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www....

08/07/2025 06:00
Art Collective teamLab to Open New Museum, teamLab Biovortex Kyoto on October 7, 2025

teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025. This will be teamLab's largest museum in Japan, spanning over 10,000 square meters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806347101/en/Even if individual elements are separated in space and time, when a structural order appears among them, the ...

09/01/2025 15:45
VERIMATRIX: Changes in Group Governance

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250901409733/en/ VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of security solutions for a safer connected world, announces the appointment, with immediate effect, of Laurent Dechaux as Chief Executive Officer, replacing Amedeo D'Angelo. Amedeo D'Angelo remains Chairman of the Board of Directors of VERIMATRIX. "We are delighted to welcome Laurent ...

08/27/2025 10:02
From Paris with Love: KARL LAGERFELD’s Fall/Winter 2025 Campaign

Paris...meet Paris. KARL LAGERFELD is proud to unveil its Fall/Winter 2025 campaign, From Paris with Love, starring global icon Paris Hilton. Blending her one-of-a-kind charisma with the brand’s unmistakable aesthetic, the campaign playfully unites two cultural forces who have shaped pop culture on their own terms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826688190/en/KARL LAGERFELD Fall Winter 25 Campaign - Paris Hilton - ...

09/17/2025 14:35
Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations

Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/Bacardi announces new roles for Dave Ingram and Nicole Zukowski. Dave Ingram has been appointed to the role of Chief People & Business Transformation Offic...

08/27/2025 10:00
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved TEVIMBRA (tislelizumab), in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by TEVIMBRA monotherapy as adjuvant treatment, for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The EC approval is based on results from the Phase 3 RATIONALE-315 trial. The preplanned f...

09/01/2025 16:00
Toshiba to Showcase the Next Generation of Retail Innovations at First NRF Retail’s Big Show in Europe

Toshiba Global Commerce Solutions will showcase how the latest retail innovations are empowering retailers to craft unique journeys and sustainably deliver success in booth #G167 - Pavilion 6 at the first-ever NRF 2025: Retail’s Big Show Europe this month. Toshiba’s new modular and customized solutions utilize advanced technology like AI, computer vision, and machine learning to meet the unique needs of retailers, no matter their size or segment. This press release features multimedia. View th...

09/17/2025 19:46
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commiss...

09/18/2025 15:45
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As pa...